

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/723,589	11/25/2003	Stanley B. Prusiner	UCAL-243	7570
	7590 03/08/2007 FIELD & FRANCIS LL	EXAMINER		
1900 UNIVERS	1900 UNIVERSITY AVENUE ROYDS, LESLIE A			LESLIE A
SUITE 200 EAST PALO A	RSITY AVENUE ROYDS, LESLIE A  ALTO, CA 94303  ART UNIT PAPER NUMBER			
	,		1614	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVER	Y MODE
30 D	30 DAYS 03/08/2007		PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.



## UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

DATE MAILED:

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.	
10/723,589					
·				EXAMINER	
			ART UNIT	PAPER	
•				20070221	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

In re Application of: Prusiner et al., "CYCLIC BIS-COMPOUNDS CLEARING MALFORMED PROTEINS"-

Application No.:

10/723,589

Filed:

25 November 2003

Attorney Docket No.: UCAL-243

## NOTICE OF NON-RESPONSIVE AMENDMENT

Applicant's responses filed 19 October 2006 and 28 December 2006 to the Requirement for Restriction/Election dated 22 September 2006, have each been received and entered into the present application. Applicant's election of (i) quinacrine as the species of biscompound and (ii) Creutzfeld-Jacob disease as the species of disease to which examination on the merits will be restricted is acknowledged.

It is noted, however, the Applicant's election of the compound "quinacrine" does not satisfy the requirements set forth in the Requirement for Restriction/Election of 22 September 2006. In particular, and as noted at page 2 of the requirement, Applicant was required to select a single disclosed species of compound from those listed in the claims. Applicant's election of "quinacrine" solely defines the R functionalities contained at either end of the linking group, but fails to define a SINGLE DISCLOSED SPECIE of compound as was required in the Office Action of 22 September 2006. Applicant is advised that the single disclosed specie of compound should be fully defined as a SINGLE CHEMICAL ENTITY, wherein the linking group and the R groups are each identified and a structural depiction of the compound is provided as was required at page 4 of the Office Action of 22 September 2006. Should Applicant again fail to elect a single disclosed specie of compound as defined by these guidelines, the reply will again be held non-responsive.

Since the above-mentioned response appears to be a bona fide attempt to reply, Applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction, as well as a proper response to the previous Office Action, in order to avoid abandonment. Extensions of this time period under 37 C.F.R. 1.136(a) are available.

Inquiry concerning this communication or earlier communications from the Examiner should be directed to Leslie A. Royds, whose telephone number is (571)-272-6096. The Examiner can normally be reached Monday through Friday, 9:00 AM to 5:30 PM. If attempts to reach the Examiner are unsuccessful, the Examiner's supervisor, Ardin H. Marschel, can be reached on (571)-272-0718. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Patent Examiner
Art Unit 1614

ARDIN H. MARSCHEL SUPERVISORY PATENT EXAMINER